Correction to: HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.

Altunay, Betül; Morgenroth, Agnieszka; Beheshti, Mohsen; Vogg, Andreas; Wong, Nicholas C L; Ting, Hong Hoi; Biersack, Hans-Jürgen; Stickeler, Elmar; Mottaghy, Felix M

Altunay, Betül; Morgenroth, Agnieszka; Beheshti, Mohsen; Vogg, Andreas; Wong, Nicholas C L; Ting, Hong Hoi; Biersack, Hans-Jürgen; Stickeler, Elmar; Mottaghy, Felix M.

Afiliação

Altunay B; Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
Morgenroth A; Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
Beheshti M; Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
Vogg A; Center of Integrated Oncology (CIO), Cologne and Düsseldorf, Universities of Aachen, Kerpener Str. 62, 50937, Bonn, Cologne, Germany.
Wong NCL; Division of Molecular PET-Imaging and Theranostics, Paracelsus Medical University, 5020, Salzburg, Austria.
Ting HH; Department of Nuclear Medicine, University Hospital Aachen, RWTH Aachen University, 52074, Aachen, Germany.
Biersack HJ; Nanomab Technology Limited, Shanghai, People's Republic of China.
Stickeler E; Nanomab Technology Limited, Shanghai, People's Republic of China.
Mottaghy FM; Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.

Eur J Nucl Med Mol Imaging ; 51(11): 3485, 2024 Sep.

Article em En | MEDLINE | ID: mdl-38900309

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google